Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sticking To My Theory

<< Previous

Bullboard Posts

Next >>

Comment by MikeStockon Mar 16, 2021 11:53am

115 Views

Post# 32807675

RE:RE:RE: Sticking To My Theory

Exactly, but we'd need to see additional terms to know if there is a forced sale at the same time. Typically the way these work is there are 2 buckets that have your name on them. One bucket is pre-vested and the other is post vest. The vesting schedule just moves shares from one bucket to the next. Once they are in the post vest bucket they are yours to sell whenever you want. Execs will have some constraints related to sale disclosures, but the vesting date and the sell date don't necessarily need to match. Typically it's left up to the individual on when they sell.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (May 31, 2024)